1150 related articles for article (PubMed ID: 25319322)
21. [Single center experience of (18F)-fluorocholine positron emission tomography: analysis of its impact on salvage local therapy in patients with prostate adenocarcinoma].
Moussaid Y; Bonardel G; Jacob J; Métivier D; Gontier E; Bauduceau O; Durand X; Fayolle M; Houlgatte A; Foehrenbach H; Védrine L; Chargari C
Cancer Radiother; 2013; 17(4):259-64. PubMed ID: 23702489
[TBL] [Abstract][Full Text] [Related]
22. ¹⁸F-choline positron emission tomography/computed tomography-driven high-dose salvage radiation therapy in patients with biochemical progression after radical prostatectomy: feasibility study in 60 patients.
D'Angelillo RM; Sciuto R; Ramella S; Papalia R; Jereczek-Fossa BA; Trodella LE; Fiore M; Gallucci M; Maini CL; Trodella L
Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):296-302. PubMed ID: 25084612
[TBL] [Abstract][Full Text] [Related]
23. 11C-choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen-deprivation therapy.
Giovacchini G; Picchio M; Garcia-Parra R; Briganti A; Abdollah F; Gianolli L; Schindler C; Montorsi F; Messa C; Fazio F
J Nucl Med; 2014 Feb; 55(2):233-41. PubMed ID: 24408897
[TBL] [Abstract][Full Text] [Related]
24. Correlation of [11C]choline PET-CT with time to treatment and disease-specific survival in men with recurrent prostate cancer after radical prostatectomy.
Breeuwsma AJ; Rybalov M; Leliveld AM; Pruim J; de Jong IJ
Q J Nucl Med Mol Imaging; 2012 Oct; 56(5):440-6. PubMed ID: 23069923
[TBL] [Abstract][Full Text] [Related]
25.
Habl G; Sauter K; Schiller K; Dewes S; Maurer T; Eiber M; Combs SE
Prostate; 2017 Jun; 77(8):920-927. PubMed ID: 28317152
[TBL] [Abstract][Full Text] [Related]
26. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography.
Rigatti P; Suardi N; Briganti A; Da Pozzo LF; Tutolo M; Villa L; Gallina A; Capitanio U; Abdollah F; Scattoni V; Colombo R; Freschi M; Picchio M; Messa C; Guazzoni G; Montorsi F
Eur Urol; 2011 Nov; 60(5):935-43. PubMed ID: 21840116
[TBL] [Abstract][Full Text] [Related]
27. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
28. Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?
Castellucci P; Fuccio C; Rubello D; Schiavina R; Santi I; Nanni C; Allegri V; Montini GC; Ambrosini V; Boschi S; Martorana G; Marzola MC; Fanti S
Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):55-63. PubMed ID: 20848281
[TBL] [Abstract][Full Text] [Related]
29. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
30. 11C-Choline PET/CT in the primary diagnosis of prostate cancer: impact on treatment planning.
Garcia JR; Jorcano S; Soler M; Linero D; Moragas M; Riera E; Miralbell R; Lomeña F
Q J Nucl Med Mol Imaging; 2015 Sep; 59(3):342-50. PubMed ID: 24844254
[TBL] [Abstract][Full Text] [Related]
31. 11C-acetate positron-emission tomography/computed tomography imaging for detection of recurrent disease after radical prostatectomy or radiotherapy in patients with prostate cancer.
Esch LH; Fahlbusch M; Albers P; Hautzel H; Müller-Mattheis V
BJU Int; 2017 Sep; 120(3):337-342. PubMed ID: 27860163
[TBL] [Abstract][Full Text] [Related]
32. Patterns of Recurrence After Postprostatectomy Fossa Radiation Therapy Identified by C-11 Choline Positron Emission Tomography/Computed Tomography.
Parker WP; Evans JD; Stish BJ; Park SS; Olivier K; Choo R; Nathan MA; Welch BT; Karnes RJ; Mynderse LA; Pisansky TM; Kwon ED; Lowe VJ; Davis BJ
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):526-535. PubMed ID: 28126302
[TBL] [Abstract][Full Text] [Related]
33. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S
J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of tumor recurrences after radical prostatectomy using 18F-Choline PET/CT and 3T multiparametric MRI without endorectal coil: a single center experience.
Couñago F; Recio M; Maldonado A; Del Cerro E; Díaz-Gavela AA; Thuissard IJ; Sanz-Rosa D; Marcos FJ; Olaciregui K; Mateo M; Cerezo L
Cancer Imaging; 2016 Dec; 16(1):42. PubMed ID: 27927229
[TBL] [Abstract][Full Text] [Related]
35. [11C]choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging.
Giovacchini G; Picchio M; Briganti A; Cozzarini C; Scattoni V; Salonia A; Landoni C; Gianolli L; Di Muzio N; Rigatti P; Montorsi F; Messa C
J Urol; 2010 Sep; 184(3):938-43. PubMed ID: 20643445
[TBL] [Abstract][Full Text] [Related]
36. [11C]Choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Preliminary results of a prospective study.
Rinnab L; Mottaghy FM; Simon J; Volkmer BG; de Petriconi R; Hautmann RE; Wittbrodt M; Egghart G; Moeller P; Blumstein N; Reske S; Kuefer R
Urol Int; 2008; 81(2):191-7. PubMed ID: 18758218
[TBL] [Abstract][Full Text] [Related]
37. 11C-choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT.
Ceci F; Castellucci P; Graziani T; Schiavina R; Brunocilla E; Mazzarotto R; Ntreta M; Lodi F; Martorana G; Fanti S
Eur J Nucl Med Mol Imaging; 2014 May; 41(5):878-86. PubMed ID: 24346416
[TBL] [Abstract][Full Text] [Related]
38. (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial.
Nanni C; Zanoni L; Pultrone C; Schiavina R; Brunocilla E; Lodi F; Malizia C; Ferrari M; Rigatti P; Fonti C; Martorana G; Fanti S
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1601-10. PubMed ID: 26960562
[TBL] [Abstract][Full Text] [Related]
39. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
[TBL] [Abstract][Full Text] [Related]
40. Radiation Treatment of Lymph Node Recurrence from Prostate Cancer: Is 11C-Choline PET/CT Predictive of Survival Outcomes?
Incerti E; Fodor A; Mapelli P; Fiorino C; Alongi P; Kirienko M; Giovacchini G; Busnardo E; Gianolli L; Di Muzio N; Picchio M
J Nucl Med; 2015 Dec; 56(12):1836-42. PubMed ID: 26405166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
